Euthasol

Main information

  • Trade name:
  • Euthasol 40% Solution for Injection
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Euthasol 40% Solution for Injection
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Pentobarbital
  • Therapeutic area:
  • Cats, Cattle, Dogs, Horses, Other, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0370/001
  • Authorization date:
  • 28-09-2011
  • EU code:
  • UK/V/0370/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:December2011

AN:00665/2010

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Euthasolvet.400mg/ml,solutionforinjection(AT,BE,EE,EL,FI,IE,IS,LT,LU,LV,

NO,PL,SE,UK)

Euthasol400mg/ml,solutionforinjection(ES,PT)

Euthasolvet.solutionforinjection(FR)

Euthasolvet.400mg/mlsolutionforinjectionfordogs,cats,rodents,rabbits,cattle,

sheep,goats,horsesandmink(IT)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Perml:

Activesubstance:

Pentobarbital(assodiumsalt) 362.9mg

(equivalentto400mgpentobarbitalsodium)

Excipient(s):

Benzylalcohol(E1519) 20mg

PatentBlueV(E131) 0.01mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection.

Clearblueliquid.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs,cats,rodents,rabbits,cattle,sheep,goats,horsesandmink.

4.2 Indicationsforuse,specifyingthetargetspecies

Euthanasia

4.3 Contraindications

Donotuseforanaesthesia.

Issued:December2011

AN:00665/2010

Page2of6

4.4Specialwarningsforeachtargetspecies

-Intravenousinjectionofpentobarbitalhastheabilitytocauseinductionexcitement

inseveralspeciesofanimalandadequatesedationshouldbeappliedifdeemed

necessarybytheveterinarysurgeon.Measuresshouldbetakentoavoid

perivascularadministration(e.g.byusingintravenouscatheter).

-Theintraperitonealrouteofadministrationmaycauseaprolongedonsetofaction

withanincreasedriskofinductionexcitement.Intraperitonealadministrationmust

onlybeusedfollowingappropriatesedation.Measuresshouldbetakentoavoid

administrationintothespleenororgans/tissuewithlowcapacityforabsorption.This

routeofadministrationisonlysuitableforsmallanimals.

-Intracardiacinjectionmustonlybeusediftheanimalisheavilysedated,

unconscious,oranesthetized.

Toreducetheriskofinductionexcitement,euthanasiashouldbeperformedinaquiet

area.

Inhorsesandcattle,premedicationwithanappropriatesedativemustbeusedto

produceprofoundsedationbeforeeuthanasiaandanalternativemethodof

euthanasiashouldbeavailable.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

-Theintravenousrouteofadministrationshouldbetherouteofchoiceandadequate

sedationshouldbeappliedifdeemednecessarybytheveterinarysurgeon.For

horsesandcattlepremedicationismandatory.

Whereintravenousadministrationisimpossible,andonlyfollowingdeepsedation,

theproductmaybeadministeredviatheintracardiacrouteinallnamedspecies.

Alternatively,forsmallanimalsonly,administrationviatheintraperitonealroutecould

beused,followingappropriatesedation.

-Intheeventofaccidentaladministrationtoananimalnotpresentedforeuthanasia,

measuressuchasartificialrespiration,administrationofoxygenandtheuseof

analepticsareappropriate.

-Ingestionofeuthanasedanimalsbyotheranimalsmayleadtointoxication,

anaesthesiaandevendeath.Barbituratesarealsohighlystabletocooking

temperature.Duetotheriskofsecondaryintoxicationanimalseuthanasedwiththe

veterinarymedicinalproductshouldnotbefedtootheranimalsbutshouldbe

disposedofinaccordancewithnationallegislationandinamannerthatother

animalscannothaveaccesstothecarcasses.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Pentobarbitalisapotenthypnoticandasedative,andthuspotentiallytoxicinman.It

canbeabsorbedsystemicallythroughtheskinandifswallowed.Particularcare

shouldbetakentoavoidaccidentalingestionandself-injection.

Issued:December2011

AN:00665/2010

Page3of6

Incaseofaccidentalself-injection,ingestionorspillageontoskinorintoeyes,seek

medicaladviceimmediatelyandshowthepackageleafletorthelabeltothe

physician.DONOTdriveassedationmayoccur.

Incaseofaccidentalself-injection,obtainURGENTmedicalattention,advising

medicalservicesofbarbituratepoisoning.

Incaseofspillageontoskin,washtheexposedskinimmediatelyafterexposurewith

largeamountofwater.

Incaseofcontactwitheyes,rinseimmediatelywithplentyoffreshwaterandobtain

medicaladvice.

Incaseofingestion,washoutmouthandobtainmedicalattentionimmediately.

Impermeableprotectiveglovesshouldbewornwhenhandlingthisproduct.

Peoplewithknownhypersensitivitytopentobarbitalshouldavoidcontactwiththe

veterinarymedicinalproductoradministertheproductwithcaution.

AdvicetoDoctor:Theconcentrationofpentobarbitalintheproductissuchthatthe

accidentalinjectionoringestionofquantitiesassmallas1mlinhumanadultscan

haveseriousCNSeffects.Adoseofpentobarbitalsodiumof1g(equivalentto2.5ml

ofproduct)hasbeenreportedtobefatalinhumans.Treatmentshouldbesupportive

withappropriateintensivetherapyandmaintainingtherespiration.

4.6Adversereactions(frequencyandseriousness)

Minormuscletwitchingmayoccurafterinjection.

Deathmaybedelayediftheinjectionisadministeredperivascularlyorinto

organs/tissueswithlowcapacityforabsorption.Barbituratescanbeirritatingwhen

administeredperivascularly.

Pentobarbital sodium has the ability to cause induction excitement.

Premedication/sedationsignificantlyreducestheriskofexperiencinginduction

excitement.

Veryoccasionallyoneorafewgaspingrespirationsoccuraftercardiacarrest.Atthis

stagetheanimalisalreadyclinicallydead.

4.7Useduringpregnancy,lactationorlay

Ifeuthanasiaisnecessary,theproductcanbeusedinpregnantorlactatinganimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Whenanaggressiveanimalistoundergoeuthanasia,premedicationwithamore

easilyadministered(oral,subcutaneousorintramuscular)sedativeisrecommended.

Althoughpremedicationwithsedativesmaydelaythedesiredeffectoftheproduct

duetodecreasedcirculatoryfunctionthismaynotbeclinicallynoticeablesinceCNS

depressantdrugs(opioids,α2adrenoreceptoragonists,phenothiazinesetc)canalso

increasetheeffectofpentobarbital.

4.9 Amountstobeadministeredandadministrationroute

Adoseof140mg/kg,equivalentto0.35ml/kg,isconsideredsufficientforallindicated

routesofadministration.

Issued:December2011

AN:00665/2010

Page4of6

Theintravenousrouteofadministrationshouldbetherouteofchoiceandadequate

sedationshouldbeappliedifdeemednecessarybytheveterinarysurgeon.For

horsesandcattlepremedicationismandatory.

Whenintravenousadministrationisdifficult,andonlyfollowingdeepsedationor

anaesthesia,theproductmaybeadministeredviatheintracardiacroute.

Alternatively,forsmallanimalsonly,administrationviatheintraperitonealroute

couldbeused,butonlyfollowingappropriatesedation.

Theintravenousinjectionincompanionanimalsshouldbecarriedoutwitha

continuousinjectionrateuntilunconsciousnessoccurs.

Inhorsesandcattle,pentobarbitalshouldbeinjectedrapidly.

Thestoppershouldnotbepuncturedmorethan20times.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Notapplicable.

4.11Withdrawalperiod(s)

Adequatemeasuresshouldbetakentoensurethatcarcassesofanimalstreatedwith

thisproductandtheby-productsoftheseanimalsdonotenterthefoodchainandare

notusedforhumanoranimalconsumption.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:barbiturates

ATCvetcode:QN51AA01

5.1 Pharmacodynamicproperties

PentobarbitalsodiumisanoxybarbituratederivativeofBarbituricAcid.Barbiturates

depresstheentirecentralnervoussystembut,quantitatively,variousareasare

affecteddifferentlymakingtheproductapotenthypnoticandsedative.The

immediateeffectistheunconsciousnessofdeepanaesthesiafollowedby,athigh

doserates,rapiddepressionoftherespiratorycentre.Breathingstopsandcessation

ofheartactionquicklyfollowsleadingtorapiddeath.

5.2Pharmacokineticparticulars

Wheninjectedintothebloodstream,abarbiturateionises,thedegreedependingon

thedissociationconstantoftheagentandthepHoftheblood.Barbituratesbindwith

plasmaproteins,forminganequilibriumofboundandunbounddrugincirculating

blood.Cellpenetrationcanonlyoccurwiththeundissociatedform.

Aftercellpenetration,dissociationagainoccursandbindingofthedrugto

intracellularorganellestakesplace.

Tissuechangesduetocellularpenetrationandintracellularbindinghavenotbeen

described.Ingeneral,theeffectsontissuescanbecategorisedasdirectand

indirect.Ingeneral,theseeffectsaresubtleandlittleisknownconcerningthem.

Followingintracardiacuseunconsciousnessisalmostimmediateandcardiacarrest

followswithin10seconds.

Issued:December2011

AN:00665/2010

Page5of6

Followingintravenoususeunconsciousnessfollowsin5-10secondsafter

completionofadministration.

Deathfollows5-30secondslater.Intraperitoneally,euthanasiaisachievedin3-10

minutes(duetodepressionoftherespiratorycentre,theanimalmaybeclinically

deadpriorcardiacarrest).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Benzylalcohol(E1519)

PatentBlueV(E131)

Ethanol(96percent)

Propyleneglycol

Waterforinjections

6.2Incompatibilities

Donotmixwithothermedicinalproducts.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days

6.4.Specialprecautionsforstorage

Donotfreeze.

Storeintheoriginalpackagingtoprotectfromlight.

6.5Natureandcompositionofimmediatepackaging

100mlcolourlesstypeIIglassvialwithalightgreybromobutylrubberstopperandan

aluminiumcap.

250mlcolourlesstypeIIglassvialwithadarkgreybromobutylrubberstopperand

analuminiumcap.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

Issued:December2011

AN:00665/2010

Page6of6

7. MARKETINGAUTHORISATIONHOLDER

LeVetB.V.

Wilgenweg7

3421TVOudewater

TheNetherlands

8.MARKETINGAUTHORISATIONNUMBER

Vm19994/4016

9.DATEOFFIRSTAUTHORISATION

12December2011

10.DATEOFREVISIONOFTHETEXT

December2011

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Administrationonlybyaveterinarysurgeon.

Tobesuppliedonlyonveterinaryprescription.

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

31-8-2018

Public Notification: PremierZen Gold 4000 contains hidden drug ingredient

Public Notification: PremierZen Gold 4000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use PremierZen Gold 4000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

14-6-2018

Blokhuis: maak postnatale depressie bespreekbaar

Blokhuis: maak postnatale depressie bespreekbaar

In Nederland ontwikkelen jaarlijks ruim 23.400 vrouwen een depressie na de bevalling. Dat is 1 op de 8 moeders. Velen van hen durven hun situatie niet aan te kaarten. Zij zijn bang om gezien te worden als een slechte moeder (47,4%) en willen anderen niet belasten (52,2%), blijkt uit een peiling onder vrouwen die (signalen van) een postnatale depressie hebben gehad. Hierdoor blijft postnatale depressie, ook wel postpartum depressie (PPD) genoemd, te vaak onbesproken. Daarom geeft staatssecretaris Paul Blo...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

19-6-2015

Global operation against illicit medicines completed

Global operation against illicit medicines completed

A global medicine operation results in 156 arrests and shutdown of more than 2,400 websites.

Danish Medicines Agency

25-7-2018

#FDA issues updated safety communication for Zoll LifeVest 4000 regarding “Message Code 102,” and updated patient checklist.  https://go.usa.gov/xUEPn  #MedicalDevices

#FDA issues updated safety communication for Zoll LifeVest 4000 regarding “Message Code 102,” and updated patient checklist. https://go.usa.gov/xUEPn  #MedicalDevices

#FDA issues updated safety communication for Zoll LifeVest 4000 regarding “Message Code 102,” and updated patient checklist. https://go.usa.gov/xUEPn  #MedicalDevices

FDA - U.S. Food and Drug Administration

29-5-2018

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Active substance: (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine) - Transfer of orphan designation - Commission Decision (2018)3402 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/185/14/T/01

Europe -DG Health and Food Safety